Versicor announces fourth quarter 2001 financial results

For the fourth quarter of 2001, total revenues were $1.6 million compared with $1.7 million in the fourth quarter of 2000. Total operating expenses were $12.4 million for the fourth quarter of 2001 compared with $8.1 million for the fourth quarter of 2000. The increase in operating expenses resulted principally from expanded clinical trials. For the fourth quarter of 2001, Versicor reported a net loss of $10.5 million, or a loss per share of $0.45 on 23.2 million weighted average shares outstanding. This compares to a net loss of $5.1 million in the fourth quarter of...

Want to see the full article?

• Purchase this article for only $3.00